Table 2.
AMR characteristics of patients treated with belatacept plus bortezomib (B/B)
| Indication Biopsy Findings | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient | Days to dnDSA | Days to C4d+ Biopsy | Days to Bela | Days to Bort | Months Post-Tx Follow-up | DSAs (Peak MFI) | Prior AMR Treatment | t | v | i | g | ci | ct | cg | mm | cv | ah | ptc | C4d | other |
| 1 | 12 | 20 | 21 | 24 | 30 | A68 (10,959) B37 (14,251) DP3 (17,144) DQ5 (6,870) |
PP, IVIG, steroids | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 3 | ATN, TMA |
| 2 | 11 | 11 | 19 | 14 | 29 | A3 (2086) DP1(18452) DP3 (3,153) |
PP, ATG, IVIG, steroids | 3 | - | 2 | 2 | 0 | 0 | 0 | 0 | - | 0 | 3 | 3 | ATN, IH |
| 3 | 25 | ND | 32 | 32 | 22 | B8 (3994) B51 (8583) C1 (5015) DR53 (2564) |
PP, IVIG, steroids | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 4 1st episode |
0 | 11 | 17 | 21 | - | DR7 (6,803) DR53 (6568) DQ2 (12756) DQ6 (2949) |
PP, IVIG, steroids | 3 | - | 2 | 0 | 0 | 0 | 0 | 0 | - | 0 | 2 | 3 | ATN |
| 4 2nd episode |
31 | 82 | ongoing | 115 | 18 | DR7 (3,744) | PP, IVIG, steroids, B/B | 1 | - | 2 | 0 | 1 | 1 | 0 | 0 | - | 0 | 0 | 1 | - |
| 5 | 6 | 6 | 14 | 9 | 10 | DQ7 (6373) DRB1*04 (3751) DRB1*14 (2314) DR52 (2847) |
PP, IVIG, steroids | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ATN, IH, Necrosis |
| 6 | 290 | 291 | 292 | 292 | 26 | A1 (6861) B8 (4505) B44 (2,519) DQ2 (14178) |
PP, IVIG, steroids | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 2 | 0 | 2 | 3 | ATN, TMA |